Federal courts in Delaware, Indiana, and New Jersey yesterday issued orders related to the federal government’s May 17 demand to six drug manufacturers to immediately resume unrestricted 340B pricing on drugs shipped to contract pharmacies.
The government last week asked AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics to provide an update by next Tuesday, June 1, on their plans for resuming 340B pricing when covered entities contract with outside pharmacies. It said decisions about whether to impose civil fines on the companies of up to $5,883.00 for each instance of 340B overcharging would be based on each company’s willingness to comply.
Federal courts in Delaware, Indiana, and New Jersey yesterday issued orders related to the federal government’s May 17 demand to six drug manufacturers to immediately resume unrestricted 340B pricing on drugs shipped to contract pharmacies. The government asked AstraZeneca, Eli Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics to provide an update by next Tuesday, June 1, on their plans for resuming 340B pricing when covered entities contract with outside pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
